Capital Fund Management (CFM)’s Alnylam Pharmaceuticals ALNY Stock Holding History

Capital Fund Management (CFM)’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-9,900	Closed	-$1.08M	–	1003
2020 Q1	$1.08M	Buy	+9,900	New	+$1.14M	0.02%	758
2018 Q4	–	Sell	-22,400	Closed	-$1.96M	–	1813
2018 Q3	$1.96M	Buy	22,400 +14,500	+184%	+$1.46M	0.01%	1125
2018 Q2	$778K	Buy	7,900 +5,800	+276%	+$575K	﹤0.01%	1430
2018 Q1	$250K	Sell	2,100 -26,900	-93%	-$3.47M	﹤0.01%	1690
2017 Q4	$3.68M	Buy	29,000 +26,200	+936%	+$3.29M	0.02%	771
2017 Q3	$329K	Hold	2,800	–	–	﹤0.01%	1297
2017 Q2	$223K	Buy	+2,800	New	+$179K	﹤0.01%	1359
2016 Q2	–	Sell	-3,500	Closed	-$220K	–	1493
2016 Q1	$220K	Buy	+3,500	New	+$233K	﹤0.01%	1413
2014 Q2	–	Sell	-4,600	Closed	-$309K	–	1646
2014 Q1	$309K	Buy	+4,600	New	+$356K	﹤0.01%	1461
2013 Q4	–	Sell	-5,900	Closed	-$378K	–	1638
2013 Q3	$378K	Buy	+5,900	New	+$294K	0.01%	1269

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Fund Management (CFM)'s ALNY Position: Q1 2026 in Review

Capital Fund Management (CFM) increased its Alnylam Pharmaceuticals (ALNY) stake by 569% in Q1 2026, buying an estimated $40.6M and bringing the position to 140,109 shares worth $46.4M. The position accounts for 0.21% of the portfolio, ranked #86.

Capital Fund Management (CFM) first reported a position in ALNY in Q4 2013 and has held it in 14 quarters since. 787 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

Capital Fund Management (CFM) held 140,109 shares of Alnylam Pharmaceuticals worth $46.4M as of Q1 2026.
Capital Fund Management (CFM) bought 119,169 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $40.6M.
Alnylam Pharmaceuticals made up 0.21% of Capital Fund Management (CFM)'s portfolio in Q1 2026, its #86 holding.
Capital Fund Management (CFM) first reported a position in Alnylam Pharmaceuticals in Q4 2013 and has held it in 14 quarters since.
787 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Capital Fund Management (CFM)'s 13F filing for Q1 2026, filed 14 May 2026.